What Is Mazdutide? China's New Obesity Drug, Explained for U.S. Readers

Retatrutide research context

Retatrutide is investigational, is not FDA-approved and cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell it. Percentages from separate trials do not establish superiority, and an average does not predict an individual outcome. The cited evidence does not establish sex-specific regimens or validate combinations with other drugs. No FDA approval date has been established.

Key Takeaways

• Mazdutide is a once-weekly injectable GLP-1/glucagon dual agonist discovered by Eli Lilly
• Lilly licensed Greater China rights to Innovent Biologics; Innovent runs Chinese clinical development and commercialization
• China's NMPA approved mazdutide for chronic weight management on June 27, 2025 and for type 2 diabetes on September 19, 2025 (Innovent); the brand name is Xinermei (信尔美)
• The pivotal obesity trial was GLORY-1 (NEJM, 2025): 48-week weight change of -11.00 percent at 4 mg and -14.01 percent at 6 mg versus +0.30 percent with placebo; the approved doses are 4 mg and 6 mg

Direct answer

Mazdutide is a once-weekly injectable peptide that activates both GLP-1 and glucagon receptors. It was discovered by Eli Lilly and licensed to Innovent Biologics for development in China. On June 27, 2025 China's NMPA approved mazdutide (brand Xinermei) for chronic weight management on the strength of GLORY-1, a 48-week phase 3 trial in 610 Chinese adults that reported -11.00 percent weight change at 4 mg and -14.01 percent at 6 mg versus +0.30 percent with placebo (NEJM, 2025); a type 2 diabetes approval followed on September 19, 2025. Mazdutide is not approved by the U.S. FDA. Lilly has run a U.S. phase 2 trial (published August 21, 2026), but no phase 3 or U.S. filing had been announced as of September 5, 2026. Correction, September 2026: an earlier version named the brand Sineipasy, dated the approval to May 2025 and attributed a 14.4 percent result to a 9 mg dose in DREAMS-1. All three were wrong and have been corrected.

Regulatory status as of September 2026

Mazdutide is approved only in China: for chronic weight management on June 27, 2025 and for glycemic control in type 2 diabetes on September 19, 2025 (Innovent Biologics). As of September 5, 2026 it is not approved by the FDA or, as far as we could find, by any regulator outside China. In the United States it is investigational: Lilly has published a phase 2 trial (The Lancet Diabetes and Endocrinology, August 21, 2026) and has not announced a phase 3 or an FDA filing. Mazdutide is not a component of any FDA-approved drug, so no U.S. pharmacy can lawfully compound or dispense it. FDA's compounding page (content current September 1, 2026) states that FDA has warned companies selling mazdutide labeled 'for research purposes,' and its December 10, 2024 warning letter to Summit Research Peptides named mazdutide among unapproved drugs sold as research chemicals. FormBlends does not prescribe, compound, sell or supply mazdutide.

Table of contents

1. Regulatory status as of September 2026
2. The Lilly-Innovent partnership
3. The molecule and its development code
4. Why this drug is a China story
5. The DREAMS clinical trial program
6. What the DREAMS-1 obesity data actually showed
7. How mazdutide compares to other GLP-1 class drugs
8. Side-effect profile
9. U.S. regulatory status (or lack of one)
10. The "mazdutide for sale" problem
11. The contrary view: should anyone outside China care?
12. Corrections, September 2026
13. Side effects with numbers
14. FAQ
15. Sources

The Lilly-Innovent partnership

Eli Lilly maintains a substantial Chinese partnership network for selected molecules. The Lilly-Innovent mazdutide collaboration was disclosed in 2019. Under the partnership:

• Lilly discovered the molecule (code LY3305677) and licensed it to Innovent in August 2019 for development and commercialization in China
• Innovent Biologics holds the China rights under that 2019 agreement
• Innovent leads the Chinese clinical program (the GLORY trials in obesity and the DREAMS trials in type 2 diabetes)
• Innovent handles manufacturing for the Chinese market
• Innovent markets the product under the brand Xinermei (信尔美) in China

This partnership structure is increasingly common in pharma. Multinational companies license molecules to regional partners with local regulatory and commercial expertise. The strategy lets the local partner navigate country-specific regulatory pathways and clinical trial requirements while the originator maintains other-market rights.

The molecule and its development code

Mazdutide's Lilly development code is LY3305677. The molecule is a synthetic peptide combining structural elements of GLP-1 and glucagon, engineered for receptor binding at both. The receptor selectivity ratio is part of the design; mazdutide's published profile shows balanced activity with a slight tilt toward glucagon receptor activation, which produces hepatic effects on lipid metabolism.

The molecule is administered by once-weekly subcutaneous injection. Doses studied include 4 mg and 6 mg (GLORY-1, the approved doses), 9 mg (GLORY-2) and, in the U.S. phase 2 trial, 3 to 6 mg, 10 mg and 16 mg. Higher doses produced larger weight loss: -18.55 percent overall and -20.08 percent in participants without type 2 diabetes at 60 weeks with 9 mg (GLORY-2, JAMA 2026), and -18.1 percent at 32 weeks with 16 mg (U.S. phase 2). Correction, September 2026: an earlier version listed a 4.5 mg dose, which we could not find in any trial.

Why this drug is a China story

Several factors explain why mazdutide became a China-focused product:

China's obesity market is emerging. Obesity rates in China have risen sharply over the past two decades. The Chinese government and pharmaceutical regulatory landscape now recognize obesity as a treatable condition. China's NMPA has been receptive to new obesity therapies.

Local clinical evidence requirements. Chinese regulators have historically preferred or required local clinical trials in Chinese populations. The GLORY and DREAMS programs were designed to generate this evidence.

Innovent's commercial network. Innovent has established commercial infrastructure in China; Lilly accelerates market access through the partnership.

The DREAMS clinical trial program

Innovent's Chinese phase 3 program runs under two names: GLORY for obesity and DREAMS for type 2 diabetes. Correction, September 2026: an earlier version of this table listed DREAMS-1 as the obesity trial and included a 'DREAMS-4' and 'MAH studies'; DREAMS-1 is a type 2 diabetes trial, and we found no DREAMS-4 among the 41 mazdutide records on ClinicalTrials.gov. The table has been rebuilt.

Trial	Population	Status
GLORY-1 (NCT05607680)	610 Chinese adults with obesity or overweight, 4 mg and 6 mg, 48 weeks	Published NEJM June 2025; supported the June 27, 2025 approval
GLORY-2 (NCT06164873)	462 Chinese adults with BMI 30 or higher, 9 mg, 60 weeks	Published JAMA August 4, 2026; Innovent said an NDA for 9 mg is planned (November 19, 2025)
GLORY-3 (NCT06884293)	Head-to-head versus semaglutide	Registered
GLORY-OSA (NCT06931028)	Obstructive sleep apnea with obesity	Registered
DREAMS-1	Type 2 diabetes, monotherapy, 24 weeks	HbA1c -2.15 versus -0.14 percent; weight -7.81 versus -1.26 percent (Innovent, September 19, 2025)
DREAMS-2	Type 2 diabetes versus dulaglutide, 28 weeks	HbA1c -1.73 versus -1.38 percent; weight -9.24 versus -2.86 percent (Innovent, September 19, 2025)
DREAMS-3 (NCT06184568)	Type 2 diabetes versus semaglutide	Completed September 2025
Adolescents (NCT07255209); MASH (NCT06937749)	Special populations, China	Registered

These trials enrolled Chinese adults, reflecting the regulatory and commercial focus of the program. The U.S. data come from Lilly's separate phase 2 trial.

What the DREAMS-1 obesity data actually showed

GLORY-1 (Ji L et al., NEJM 2025;392:2215-2225; NCT05607680) randomized 610 Chinese adults with a BMI of 28 or higher, or 24 or higher with a weight-related condition, to placebo or mazdutide 4 mg or 6 mg for 48 weeks. Correction, September 2026: this section previously described DREAMS-1, which is a type 2 diabetes trial; the figures below are from GLORY-1.

Arm	Mean weight change (48 weeks)
Mazdutide 6 mg	-14.01%
Mazdutide 4 mg	-11.00%
Placebo	+0.30%

At week 48, 35.7 percent of the 4 mg group, 49.5 percent of the 6 mg group and 2.0 percent of the placebo group had lost at least 15 percent of body weight; discontinuation for adverse events was 1.5, 0.5 and 1.0 percent (NEJM, 2025). Innovent's June 27, 2025 release states the efficacy-estimand results as 12.0 and 14.8 percent versus 0.5 percent.

Two important interpretive notes:

Note 1: Population differences matter. Chinese populations have a lower mean BMI at obesity diagnosis than U.S. populations (BMI ≥28 is the China threshold; BMI ≥30 is the WHO global threshold). Absolute pounds lost are smaller in the GLORY-1 population than would be expected in a U.S. population with the same percentage loss.

Note 2: Cross-trial comparison is unfair. The 14.01 percent figure cannot be directly compared to SURMOUNT-1, where tirzepatide 15 mg produced -20.9 percent at 72 weeks (NEJM, 2022), because populations, baseline BMI, lifestyle interventions and durations differ. Correction, September 2026: an earlier version cited SURMOUNT-1 as about 22.5 percent and a REDEFINE-1 figure we could not verify; both have been replaced or removed. Cross-trial cuts both ways: tirzepatide may produce more weight loss; mazdutide may produce a different absolute response in a different population.

How mazdutide compares to other GLP-1 class drugs

Drug	Receptor targets	Sponsor	Approval status (September 2026)
Semaglutide	GLP-1	Novo Nordisk	FDA-approved (Wegovy, Ozempic, Rybelsus)
Liraglutide	GLP-1	Novo Nordisk	FDA-approved (Saxenda, Victoza)
Tirzepatide	GLP-1 / GIP	Eli Lilly	FDA-approved (Zepbound, Mounjaro)
Mazdutide	GLP-1 / glucagon	Lilly / Innovent	Approved in China (June 2025 obesity; September 2025 type 2 diabetes); not U.S.
Survodutide	GLP-1 / glucagon	Boehringer / Zealand	Investigational, phase 3

Mazdutide is mechanistically similar to survodutide (both are GLP-1/glucagon dual agonists), but the molecules differ in peptide structure, receptor selectivity, and pharmacokinetics. The two drugs may eventually show different weight-loss efficacy and tolerability profiles even within the same class.

Side-effect profile

GLORY-1 reported a GI-dominant adverse-event pattern consistent with the broader GLP-1 class. Key observations:

• Nausea, diarrhea, and vomiting were the most common events, concentrated in the titration phase
• Most GI events were mild to moderate
• Discontinuation for adverse events: 1.5 percent (4 mg), 0.5 percent (6 mg) and 1.0 percent (placebo) in GLORY-1; 2.9 percent versus 0 percent in GLORY-2 (9 mg); 20 percent at 16 mg in the U.S. phase 2 trial
• Cardiometabolic measures: the GLORY-1 abstract reports beneficial effects on all prespecified cardiometabolic measures; liver-enzyme detail is not in the abstract
• Glycemic safety: no evidence of clinically meaningful hyperglycemia, presumably because the GLP-1 component offsets glucagon's acute glucose-raising effect

Specific safety questions for U.S. interpretation:

• Ethnic-specific safety: the trial was conducted in Chinese populations. Whether the same profile would hold in U.S. populations is an unknown that has not been studied
• Long-term hepatic safety: the glucagon component's effects on liver lipid metabolism in lean MASH or other liver disease phenotypes have not been characterized at the same depth as semaglutide
• Cardiovascular outcomes: no large cardiovascular outcomes trial for mazdutide has been published

U.S. regulatory status (or lack of one)

Mazdutide is not approved by the FDA. What does exist in the U.S., as of September 5, 2026: a completed Lilly phase 2 trial (NCT06124807, 179 adults, November 2023 to July 2025) that reported 32-week weight change of -7.3 percent (3 to 6 mg), -15.6 percent (10 mg) and -18.1 percent (16 mg) versus -0.9 percent with placebo, with 20 percent of the 16 mg group stopping for adverse events (The Lancet Diabetes and Endocrinology, August 21, 2026); a recruiting U.S. and Argentina phase 2 master protocol (NCT06143956); and a completed U.S. phase 2 trial in alcohol use disorder (NCT06817356). No phase 3 trial or FDA filing has been announced. Correction, September 2026: an earlier version said there was no U.S. regulatory pathway disclosed; that was out of date.

If Lilly decided to develop mazdutide for the U.S. market, the regulatory pathway would require:

• Phase 3 trials in U.S. populations, building on the phase 2 data and possibly bridging from the Chinese GLORY and DREAMS programs
• U.S. population safety and efficacy evidence (Chinese trial data alone is generally insufficient for FDA labeling)
• FDA-inspected U.S. or international manufacturing
• A new drug application with U.S.-specific labeling

The "mazdutide for sale" problem

Search demand for "mazdutide" and "mazdutide peptide" in the U.S. has risen since the China approval. The supply that filled that demand is unregulated research-grade material, not the clinical product.

FDA has acted on this market. Its December 10, 2024 warning letter to Summit Research Peptides named mazdutide among unapproved drugs offered 'for research use only,' and FDA's compounding page (content current September 1, 2026) states it has warned companies selling mazdutide labeled 'for research purposes' or 'not for human consumption.' Common patterns in the U.S. online mazdutide market:

• Powdered or pre-mixed vials sold as "research peptide"
• "For research use only" labels (which FDA enforcement reads as marketing fiction when sold to consumers for injection)
• Variable purity and potency, with no FDA-inspected manufacturing
• No way to verify the product is the same molecule used in the GLORY and DREAMS trials
• No prescriber or pharmacist involvement, no medical supervision

Personal-importation of foreign-approved drugs for personal use is generally prohibited under U.S. law for prescription medications. The FDA exercises limited discretion in cases where no U.S. equivalent exists; obesity has multiple U.S.-approved options, so this discretion is unlikely to apply to mazdutide.

The contrary view: should anyone outside China care?

From a U.S. patient perspective, mazdutide is mostly an academic curiosity. The honest case:

Argument 1: There are better U.S.-available options. Tirzepatide produces more weight loss in phase 3 trials and is FDA-approved with established infrastructure. Wegovy is also available. A U.S. patient seeking GLP-1 class treatment has appropriate options without considering mazdutide.

Argument 2: Population data matters for translation. A drug developed and approved in Chinese populations may produce different efficacy or safety in U.S. populations. Without U.S. clinical data, the China numbers should not be assumed to transfer.

Argument 3: The legal and quality risks of importing are real. Anyone attempting to obtain mazdutide outside of approved channels faces quality, legal, and clinical risks that outweigh any plausible benefit relative to U.S.-approved alternatives.

The reasonable counterpoint: mazdutide's approval in China is part of the broader internationalization of obesity medicine and an interesting data point in the dual-agonist competitive landscape. If Lilly eventually develops it for other markets, the GLORY and DREAMS evidence base, plus the U.S. phase 2 data, will support broader access. Until then, it is a China story.

Decision framework

If you live in mainland China or have legitimate access through Chinese healthcare: mazdutide (Xinermei) is a regulator-approved option at 4 mg or 6 mg. Discuss with a local clinician.

If you live in the U.S.: mazdutide is not available legally. U.S.-approved options (Wegovy, Zepbound, Saxenda) are the legitimate paths.

If you're researching the global obesity drug landscape: mazdutide's approval marks China as the first major market to approve a GLP-1/glucagon dual agonist for obesity. Whether other markets follow depends on Lilly's strategic decisions.

If you're considering purchasing mazdutide online: the product on the gray market is not the clinical drug. The quality, identity, and safety are unverifiable. Do not.

Corrections, September 2026: name, date, trial, doses

An earlier version of this page carried several errors about the Chinese approval. Each was checked against the Innovent releases, the NEJM and JAMA papers and the Drugs 'First Approval' review on September 5, 2026.

Earlier version said	Corrected to	Source
Brand name Sineipasy	Xinermei (信尔美)	Shirley M. Mazdutide: First Approval. Drugs 2025;85(12):1621-1627
Approved May 2025	June 27, 2025 (weight management); September 19, 2025 (type 2 diabetes)	Innovent releases
Pivotal trial DREAMS-1	GLORY-1 (obesity); DREAMS-1 is a type 2 diabetes trial	NEJM 2025; Innovent September 19, 2025
14.4 percent at 9 mg	-11.00 percent at 4 mg and -14.01 percent at 6 mg versus +0.30 percent placebo at 48 weeks; 9 mg was studied separately in GLORY-2 (-18.55 percent at 60 weeks)	NEJM 2025; JAMA 2026; Innovent November 19, 2025
Doses 3, 4.5, 6 and 9 mg	4 mg and 6 mg approved; 9 mg in GLORY-2; 3 to 6, 10 and 16 mg in the U.S. phase 2	NEJM 2025; JAMA 2026; Lancet Diabetes and Endocrinology 2026
No U.S. pathway disclosed	U.S. phase 2 completed and published; no phase 3 or filing announced	Lancet Diabetes and Endocrinology, August 21, 2026; ClinicalTrials.gov

Side effects with numbers

The pattern is gastrointestinal and dose related, as with other GLP-1 class drugs. The figures that have been published:

• GLORY-1 (4 and 6 mg, 48 weeks, n=610): discontinuation for adverse events 1.5 percent at 4 mg, 0.5 percent at 6 mg, 1.0 percent on placebo (NEJM, 2025).
• GLORY-2 (9 mg, 60 weeks, n=462, 16 percent with type 2 diabetes): discontinuation for adverse events 2.9 percent versus 0 percent on placebo; 44.0 percent versus 2.6 percent lost at least 20 percent of body weight (Innovent, November 19, 2025; JAMA, August 4, 2026).
• U.S. phase 2 (n=179, 32 weeks): discontinuation for adverse events reached 20 percent in the 16 mg group (The Lancet Diabetes and Endocrinology, August 21, 2026).

No cardiovascular outcomes trial has been published, and the Chinese trials do not tell us how the drug behaves in U.S. populations.

FAQ

How do you pronounce mazdutide?

Approximately "MAZ-doo-tide."

Is mazdutide the same as tirzepatide?

No. Different molecule and different receptor profile. Tirzepatide is GLP-1/GIP; mazdutide is GLP-1/glucagon.

Is mazdutide approved anywhere?

Yes, in China: NMPA approval for chronic weight management on June 27, 2025 and for type 2 diabetes on September 19, 2025 (Innovent). We found no approval outside China as of September 5, 2026.

Can I get mazdutide through a U.S. doctor?

No. A U.S. clinician cannot prescribe a drug that is not FDA-approved or commercially available in the U.S.

What is the mazdutide brand name?

Xinermei (信尔美) in China, per the Drugs journal 'Mazdutide: First Approval' review (2025). Correction, September 2026: this page previously gave the name as Sineipasy, which was wrong.

How much does mazdutide cost in China?

Pricing varies. Innovent has positioned mazdutide as a premium obesity medication in the Chinese market.

Will mazdutide come to the U.S.?

Is mazdutide better than Wegovy?

Cross-trial comparison is unreliable. The reported weight-loss numbers are roughly comparable, but the populations and trial designs differ.

Is mazdutide a triple agonist?

Is mazdutide oral?

No. Once-weekly subcutaneous injection.

Does mazdutide work for liver disease?

The glucagon component is expected to reduce hepatic fat, and a Chinese MASH trial is registered (NCT06937749), but no large mazdutide MASH trial has been published. The GLORY-1 abstract reports beneficial effects on prespecified cardiometabolic measures without liver-enzyme detail.

What are the approved mazdutide doses in China?

Four milligrams and six milligrams once weekly, the two arms of GLORY-1, which produced -11.00 and -14.01 percent weight change at 48 weeks versus +0.30 percent with placebo (NEJM, 2025; Innovent, June 27, 2025). A 9 mg dose was tested in GLORY-2 (-18.55 percent at 60 weeks) and Innovent said on November 19, 2025 that it planned a new drug application for 9 mg; that dose was not approved as of September 5, 2026.

Is there any U.S. clinical data on mazdutide?

Yes, one trial. Lilly's U.S. phase 2 study (NCT06124807) enrolled 179 adults between November 2023 and July 2025 and was published in The Lancet Diabetes and Endocrinology on August 21, 2026: 32-week weight change of -7.3 percent (3 to 6 mg), -15.6 percent (10 mg) and -18.1 percent (16 mg) versus -0.9 percent with placebo, with 20 percent of the 16 mg group stopping for adverse events. No U.S. phase 3 has been announced.

Can a U.S. compounding pharmacy make mazdutide?

Related guides

• Mazdutide clinical trial results: GLORY, DREAMS, and what the China data actually say
• Mazdutide FDA approval timeline: marketed in China, still not filed in the U.S., and easy to misread
• Drug Profile: Mazdutide (Innovent)
• Mazdutide mechanism of action explained: why GLP-1 plus glucagon changes the metabolic story

Sources

1. Ji L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1). New England Journal of Medicine. 2025;392(22):2215-2225. PubMed PMID 40421736.
2. Innovent Biologics. Mazdutide, first dual GCG/GLP-1 receptor agonist, received approval from China's NMPA for chronic weight management, June 27, 2025. https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html
3. Eli Lilly. Annual Report Pipeline Disclosure. 2024.
4. National Medical Products Administration (China). Drug Approval Documents 2025.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
7. le Roux CW et al. Survodutide for obesity (phase 2). Lancet. 2024.
8. Wang H et al. The epidemiology of obesity in China. The Lancet Diabetes & Endocrinology. 2021.
9. WHO Western Pacific Region. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. WPRO Publications. 2000 (and subsequent updates).
10. FDA. Personal Importation Policy. 2024.
11. Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024 update.
12. Shirley M. Mazdutide: First Approval. Drugs. 2025;85(12):1621-1627. PubMed PMID 41028652.
13. GLORY-2: mazdutide 9 mg in Chinese adults with obesity, 60 weeks. JAMA. 2026;336(5):377-388. PubMed PMID 42251595.
14. Lilly U.S. phase 2 trial of mazdutide (NCT06124807, n=179, 32 weeks). The Lancet Diabetes and Endocrinology, online August 21, 2026. PubMed PMID 42628555.
15. Innovent Biologics. Mazdutide received approval from China's NMPA for glycemic control in adults with type 2 diabetes, September 19, 2025. https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-received-approval-from-chinas-nmpa-for-glycemic-control-in-adults-with-type-2-diabetes-302561434.html
16. Innovent Biologics. Mazdutide 9 mg achieves up to 20.1 percent weight loss in Chinese adults with obesity (GLORY-2), November 19, 2025. https://www.prnewswire.com/news-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints-302620471.html
17. Innovent Biologics. Innovent enters a licensing agreement with Lilly to develop and commercialize a novel diabetes medicine (OXM3, mazdutide) in China, August 2019. https://www.prnewswire.com/news-releases/innovent-enters-a-licensing-agreement-with-lilly-to-develop--commercialize-a-novel-diabetes-medicine-in-china-300905146.html
18. ClinicalTrials.gov. Mazdutide study records (41 records including NCT06124807, NCT06143956, NCT06817356, NCT06164873, NCT06184568, NCT07255209, NCT06931028, NCT06937749), accessed September 5, 2026. https://clinicaltrials.gov/api/v2/studies?query.intr=mazdutide
19. U.S. Food and Drug Administration. Warning letter to Summit Research Peptides, December 10, 2024. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024
20. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current September 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
21. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216. PubMed PMID 35658024.

Footer disclaimers

Investigational/Foreign-Approved Drug Notice. Mazdutide (brand name Xinermei) is approved by China's NMPA. It is not FDA-approved in the United States and is not legally available in U.S. pharmacies or through legitimate U.S. telehealth platforms. Online vendors selling "mazdutide" are not the source of the approved clinical product.

Results Disclaimer. The GLORY-1 weight-loss figures reflect mean changes in Chinese adult populations with structured lifestyle counseling. Population, baseline BMI, and trial protocol differences mean these numbers may not extrapolate to U.S. or other populations.

Retatrutide sources

• FDA: unapproved GLP-1 drugs
• Jastreboff et al., NEJM 2023
• NCT04881760